Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.51 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.47 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.47 |
| ▸ | FABP4 | P15090 | 6/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | FABP3 | P05413 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6780169 | 0.92 | HDAC1 (0.44) | HDAC1HDAC6CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL6775629 | 0.92 | HDAC1 (0.44) | HDAC1HDAC6CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL6693631 | 0.91 | HDAC1 (0.45) | HDAC1HDAC6CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL6688522 | 0.91 | HDAC1 (0.43) | HDAC1HDAC6CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL6692851 | 0.91 | FABP4 (0.45) | HDAC1HDAC6CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL6694057 | 0.90 | MAPT (0.45) | HDAC1HDAC6CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL6782203 | 0.89 | HDAC1 (0.45) | HDAC1HDAC6CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL6691868 | 0.89 | HDAC1 (0.47) | HDAC1HDAC6CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL6693334 | 0.89 | HDAC1 (0.43) | HDAC1HDAC6CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL6773523 | 0.89 | HDAC1 (0.47) | HDAC1HDAC6CSNK2A2CSNK2BCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1395554-B1 | SUBSTITUTED CARBAZOLES AS INHIBITORS OF SPLA2 | LILLY CO ELI (US) | 2007-02-14 | — | — | EP | disclosed |
| US-6933313-B2 | Substituted carbazoles as inhibitors of sPLA2 | ELI LILLY AND COMPANY (US) | 2005-08-23 | — | — | US | disclosed |
| EP-0950657-B1 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitors | LILLY CO ELI (US) | 2004-07-14 | — | — | EP | disclosed |
| EP-0952149-B1 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | LILLY CO ELI (US) | 2004-06-09 | — | — | EP | disclosed |
| US-20040087796-A1 | Substituted carbazoles as inhibitors of spla2 | HARPER RICHARD WALTZ (US) | 2004-05-06 | — | — | US | disclosed |
| US-6713645-B1 | INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK | ELI LILLY AND COMPANY | 2004-03-30 | — | — | US | disclosed |
| EP-1395554-A1 | SUBSTITUTED CARBAZOLES AS INHIBITORS OF SPLA2 | ELI LILLY AND COMPANY (US) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002079154-A1 | SUBSTITUTED CARBAZOLES AS INHIBITORS OF SPLA2 | ELI LILLY AND COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
| US-6177440-B1 | THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR | ELI LILLY AND COMPANY | 2001-01-23 | — | — | US | disclosed |
| EP-0952149-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | ELI LILLY AND COMPANY (US) | 1999-10-27 | — | — | EP | disclosed |
| EP-0950657-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1999-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087796-A1 | Substituted carbazoles as inhibitors of spla2 | HCAR2, ALOX12, SPTLC2 | HDAC1 503/4885HDAC6 2420/4885CSNK2A2 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.